http://cellulogixstemcellfraud.com/
Cindy Miller was promised a refund by Casey Nabavi (Cellulogix International). He was to pay off the horrific amount of $25000 via monthly payments that she paid for a stem cell treatment that left her worse off than she was prior to treatment. He has failed to do this and Cindy has created a website to warn others against Nabavi and Cellulogix International. I hear of so many dissatisfied patients that really did not see improvement and were never given any certification for the purity of the cells they supposedly received after going to Nabavi. Nabavi is now doing autologous procedures luring people again with all kinds of hype.
One woman was offered a free treatment because her original treatment did zilch for her. The free treatment was available to her Nabavi said if she would just pay the $8000 in lab fees.
Who is kidding who? He needs to think again if he thinks people are going to fall for this boatload of you know what. $8000 in lab fees? What is the lab going to do to run up a tab like that? Are they fine dining after work? Quick trip to Las Vegas, maybe? The very best advice is to stay away, far, far away from Cellulogix International or any clinic that Nabavi has ties to.
Wednesday, June 24, 2009
Monday, June 15, 2009
The FDA continues to hang us out to die
http://gaia-health.com/articles51/000055-Stem-Cell-Advocacy.shtml
Just in case anyone missed this article that I wrote for the Gaia-Health site.
My blog was down for a couple of days for no rational reason that I could understand. The message just said that it was suspected of spam. Say what? I don't write spam. It is finally back up and running after having to wait a few days for them to make sure I am on the up and up I guess.
Went to a good meeting in Denver on Saturday. Dr. Schultz from Regenexx was one of the doctors who spoke there. He gave a great presentation on the use of stem cells to repair orthopedic injuries. He had the proof right there in black and white (X-rays that is).
The gal that put the rally/meeting on is named Shel. Her daughter's vision was restored after she had stem cell therapy. There were several other parents there of children who had been helped immensely with stem cell treatment, but sadly none of them were able to be treated in the U.S.
One of today's posts on the Stem Cell Pioneers forum (www.stemcellpioneers.com) tells us that India and China, analysts say, are poised to play a key role in the scientific, clinical and commercial development of stem cell research. We are really starting to take a back seat when it comes to progress in this field.
The U.S. has put itself in this position at the expense of its citizens. Other countries continue to forge ahead while we are still bickering about whether to continue funding for embryonic research that was in progress prior to President Obama's election. We are mired down in muck a knee deep that smells to high heaven of some kind of cozy agreement between Big Pharma and the FDA since the FDA has decided our own stem cells should be treated as if they were prescription drugs. We can't seem to figure it out in this country as we worry about things like the pathetic new regulation of cigarettes or the writing on a Cheerio's box. If you care about all this, get on your high horse. Join ASCTA to start with - www.safestemcells.org Then get it in gear and e-mail the FDA with your comments and also all of your legislators and the President of the United States himself.
Folks - The FDA is hanging us out to die. We have to rise up against this leg hold that they have on the desperately sick people in this country. I am fed up with it all - the media, legislators, some forums and blogs, ignorant people claiming they are concerned for our safety. We need the liberty to choose for ourselves if we want to have our own stem cells used in treatment that could possibly save our lives. This is up to us to decide, not some third party entity that has no clue what pain we are living with 24/7.
Just in case anyone missed this article that I wrote for the Gaia-Health site.
My blog was down for a couple of days for no rational reason that I could understand. The message just said that it was suspected of spam. Say what? I don't write spam. It is finally back up and running after having to wait a few days for them to make sure I am on the up and up I guess.
Went to a good meeting in Denver on Saturday. Dr. Schultz from Regenexx was one of the doctors who spoke there. He gave a great presentation on the use of stem cells to repair orthopedic injuries. He had the proof right there in black and white (X-rays that is).
The gal that put the rally/meeting on is named Shel. Her daughter's vision was restored after she had stem cell therapy. There were several other parents there of children who had been helped immensely with stem cell treatment, but sadly none of them were able to be treated in the U.S.
One of today's posts on the Stem Cell Pioneers forum (www.stemcellpioneers.com) tells us that India and China, analysts say, are poised to play a key role in the scientific, clinical and commercial development of stem cell research. We are really starting to take a back seat when it comes to progress in this field.
The U.S. has put itself in this position at the expense of its citizens. Other countries continue to forge ahead while we are still bickering about whether to continue funding for embryonic research that was in progress prior to President Obama's election. We are mired down in muck a knee deep that smells to high heaven of some kind of cozy agreement between Big Pharma and the FDA since the FDA has decided our own stem cells should be treated as if they were prescription drugs. We can't seem to figure it out in this country as we worry about things like the pathetic new regulation of cigarettes or the writing on a Cheerio's box. If you care about all this, get on your high horse. Join ASCTA to start with - www.safestemcells.org Then get it in gear and e-mail the FDA with your comments and also all of your legislators and the President of the United States himself.
Folks - The FDA is hanging us out to die. We have to rise up against this leg hold that they have on the desperately sick people in this country. I am fed up with it all - the media, legislators, some forums and blogs, ignorant people claiming they are concerned for our safety. We need the liberty to choose for ourselves if we want to have our own stem cells used in treatment that could possibly save our lives. This is up to us to decide, not some third party entity that has no clue what pain we are living with 24/7.
Friday, June 12, 2009
Ethics in Washington? Not hardly. Key Senators have ties to health care industry.
Is this article a surprise to anyone? It surely was not to me. This type of thing is at the very core of what we are fighting in order to legalize treatment with our own stem cells. I don't believe that ethics is a word that is understood in Washington. I also just got word that my blog and the blogs of others are under review as possible spam. What????????????????????? Maybe, my blog is under review for openly criticizing the FDA and legislators like those in this article. That's a real scary thought.
By LARRY MARGASAK and SHARON THEIMER, Associated Press Writers Larry Margasak And Sharon Theimer, Associated Press Writers – 32 mins ago
WASHINGTON – Influential senators working to overhaul the nation's health care system have investments and family ties with some of the biggest names in the industry. The wife of Sen. Chris Dodd, the lawmaker in charge of writing the Senate's bill, sits on the boards of four health care companies.
Members of both parties have industry connections, including Democrats Jay Rockefeller and Tom Harkin, in addition to Dodd, and Republicans Tom Coburn, Judd Gregg, John Kyl and Orrin Hatch, financial reports showed Friday. .
Jackie Clegg Dodd, wife of the Connecticut Democrat, is on the boards of Javelin Pharmaceuticals Inc., Cardiome Pharma Corp., Brookdale Senior Living and Pear Tree Pharmaceuticals.
Dodd is filling in for ailing Sen. Edward Kennedy, D-Mass., chairman of the Health, Education, Labor and Pensions Committee, which will soon start work on a health care bill.
Other publicly available documents show Mrs. Dodd last year was one of the most highly compensated non-employee members of the Javelin Pharmaceuticals Inc. board, on which she has served since 2004. She earned $32,000 in fees and $109,587 in stock option awards last year, according to the company's SEC filings.
Mrs. Dodd earned $79,063 in fees from Cardiome in its last fiscal year, while Brookdale Senior Living gave her $122,231 in stock awards in 2008, their SEC filings show. She earned no income from her post as a director for Pear Tree Pharmaceuticals but holds up to $15,000 in stock in Pear Tree, which describes itself as a development-stage pharmaceutical company focused on the needs of aging women.
The annual financial disclosure reports for members of Congress are less precise. They only require that assets and liabilities be listed in ranges of values.
Dodd was granted a 90-day extension to file his report covering last year, but released it to The Associated Press.
Bryan DeAngelis, Dodd's spokesman, said, "Jackie Clegg Dodd's career is her own; absolutely independent of Senator Dodd, as it was when they married 10 years ago. The senator has worked to reform our health care system for decades, and nothing about his wife's career is relevant at all to his leadership of that effort."
DeAngelis said that Mrs. Dodd has hired a personal ethics lawyer to avoid any conflicts of interest and is not a lobbyist.
Other reports showed:
• Rockefeller, D-W.Va., reported $15,001 to $50,000 in capital gains for his wife from the sale of a stake in Athenahealth Inc., a business services company that helps medical providers with billing and clinical operations.
Rockefeller is honorary chairman of the Alliance for Health Reform, a Washington nonprofit whose board includes representatives from the UnitedHealth Group health insurance company; AFL-CIO labor union; the AARP, which sells health insurance; St. John Health, a nonprofit health system that includes seven hospitals and 125 medical facilities in southeast Michigan; CIGNA Corp., an employer-sponsored benefits company; and the United Hospital Fund of New York.
• Coburn, R-Okla., is a practicing physician. He reported slight business income, $268, from the Muskogee Allergy Clinic last year; $3,000 to $45,000 in stock in Affymetrix Inc., a biotechnology company and pioneer in genetic analysis; $1,000 to $15,000 in stock in Pfizer Inc., a pharmaceutical company; and a $1,000 to $15,000 interest in Thomas A. Coburn, MD, Inc.
Under Senate ethics rules, Coburn can't accept money from his patients.
• Gregg, R-N.H., disclosed $250,001 to $500,000 in drug maker Bristol-Myers Squibb Co. stock and $1,000 to $15,000 each in stock in pharmaceutical companies Merck & Co. and Pfizer, the Johnson & Johnson health care products company and Agilent Technologies, which is involved in the biomedical industry.
• Kyl, R-Ariz., the Senate minority whip, reported $15,001 to $50,000 in stock in Amgen Inc., which develops medical therapeutics. Kyl's retirement account held stakes in several health care businesses, including the Wyeth, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer and AstraZeneca pharmaceutical companies; medical provider Tenet Healthcare Corp.; CVS Caremark prescription and health services company; Genentech, a biotherapeutics manufacturer; and insurer MetLife Inc.
• Harkin, D-Iowa, has a joint ownership stake in health-related stocks. Harkin and his wife, Ruth Raduenz, own shares of drug makers Amgen and Genentech, Inc., each stake valued at $1,001 to $15,000; Their largest health care holding, Johnson & Johnson, was valued at $50,001 to $100,000.
• Hatch, R-Utah, a member of the Finance and Health committees, reported owning between $1,001 and $15,000 worth of stock in drug maker Pfizer Inc. He spoke to two pharmaceutical industry conferences last year. Sponsors of the conferences donated $3,500 to charities instead of speaking fees, as required by Senate rules.
Like millions of Americans, several senators took a financial hit in 2008. A sampling:
_Sen. Dick Durbin, D-Ill., lost some $100,000 in equity in his home in Springfield and $35,000 in his Chicago condominium. Durbin, who released his tax returns, reported losing $32,259 in various investments last year, including more than $10,400 in Berkshire Hathaway and $5,535 in Fidelity stock.
_Kennedy in 2007 had four trusts each valued between $5,000,001-$25 million. In 2008, only one trust was still in that category while the rest had slipped in value to $1,000,001-$5 million.
_Hatch's investments suffered from the banking crisis. In 2007, he reported assets of between $2,002 and $30,000 in Countrywide Credit Industries Inc. stock. His 2008 financial disclosure lists the value at less than $1,000.
One of Dodd's investments showed a vast improvement.
A new appraisal more than doubled the value of his vacation cottage in Ireland, which has been subject of a Senate ethics complaint filed by a conservative group questioning if the undervalued property was really a gift.
The property is valued at 470,000 euros, or about $660,000, on Dodd's disclosure report.
The previous year's report valued the seaside home, located in County Galway, at between $100,001 and $250,000.
DeAngelis, the spokesman, said Dodd and his wife decided to have the property appraised because they felt it was time to update the information.
By LARRY MARGASAK and SHARON THEIMER, Associated Press Writers Larry Margasak And Sharon Theimer, Associated Press Writers – 32 mins ago
WASHINGTON – Influential senators working to overhaul the nation's health care system have investments and family ties with some of the biggest names in the industry. The wife of Sen. Chris Dodd, the lawmaker in charge of writing the Senate's bill, sits on the boards of four health care companies.
Members of both parties have industry connections, including Democrats Jay Rockefeller and Tom Harkin, in addition to Dodd, and Republicans Tom Coburn, Judd Gregg, John Kyl and Orrin Hatch, financial reports showed Friday. .
Jackie Clegg Dodd, wife of the Connecticut Democrat, is on the boards of Javelin Pharmaceuticals Inc., Cardiome Pharma Corp., Brookdale Senior Living and Pear Tree Pharmaceuticals.
Dodd is filling in for ailing Sen. Edward Kennedy, D-Mass., chairman of the Health, Education, Labor and Pensions Committee, which will soon start work on a health care bill.
Other publicly available documents show Mrs. Dodd last year was one of the most highly compensated non-employee members of the Javelin Pharmaceuticals Inc. board, on which she has served since 2004. She earned $32,000 in fees and $109,587 in stock option awards last year, according to the company's SEC filings.
Mrs. Dodd earned $79,063 in fees from Cardiome in its last fiscal year, while Brookdale Senior Living gave her $122,231 in stock awards in 2008, their SEC filings show. She earned no income from her post as a director for Pear Tree Pharmaceuticals but holds up to $15,000 in stock in Pear Tree, which describes itself as a development-stage pharmaceutical company focused on the needs of aging women.
The annual financial disclosure reports for members of Congress are less precise. They only require that assets and liabilities be listed in ranges of values.
Dodd was granted a 90-day extension to file his report covering last year, but released it to The Associated Press.
Bryan DeAngelis, Dodd's spokesman, said, "Jackie Clegg Dodd's career is her own; absolutely independent of Senator Dodd, as it was when they married 10 years ago. The senator has worked to reform our health care system for decades, and nothing about his wife's career is relevant at all to his leadership of that effort."
DeAngelis said that Mrs. Dodd has hired a personal ethics lawyer to avoid any conflicts of interest and is not a lobbyist.
Other reports showed:
• Rockefeller, D-W.Va., reported $15,001 to $50,000 in capital gains for his wife from the sale of a stake in Athenahealth Inc., a business services company that helps medical providers with billing and clinical operations.
Rockefeller is honorary chairman of the Alliance for Health Reform, a Washington nonprofit whose board includes representatives from the UnitedHealth Group health insurance company; AFL-CIO labor union; the AARP, which sells health insurance; St. John Health, a nonprofit health system that includes seven hospitals and 125 medical facilities in southeast Michigan; CIGNA Corp., an employer-sponsored benefits company; and the United Hospital Fund of New York.
• Coburn, R-Okla., is a practicing physician. He reported slight business income, $268, from the Muskogee Allergy Clinic last year; $3,000 to $45,000 in stock in Affymetrix Inc., a biotechnology company and pioneer in genetic analysis; $1,000 to $15,000 in stock in Pfizer Inc., a pharmaceutical company; and a $1,000 to $15,000 interest in Thomas A. Coburn, MD, Inc.
Under Senate ethics rules, Coburn can't accept money from his patients.
• Gregg, R-N.H., disclosed $250,001 to $500,000 in drug maker Bristol-Myers Squibb Co. stock and $1,000 to $15,000 each in stock in pharmaceutical companies Merck & Co. and Pfizer, the Johnson & Johnson health care products company and Agilent Technologies, which is involved in the biomedical industry.
• Kyl, R-Ariz., the Senate minority whip, reported $15,001 to $50,000 in stock in Amgen Inc., which develops medical therapeutics. Kyl's retirement account held stakes in several health care businesses, including the Wyeth, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer and AstraZeneca pharmaceutical companies; medical provider Tenet Healthcare Corp.; CVS Caremark prescription and health services company; Genentech, a biotherapeutics manufacturer; and insurer MetLife Inc.
• Harkin, D-Iowa, has a joint ownership stake in health-related stocks. Harkin and his wife, Ruth Raduenz, own shares of drug makers Amgen and Genentech, Inc., each stake valued at $1,001 to $15,000; Their largest health care holding, Johnson & Johnson, was valued at $50,001 to $100,000.
• Hatch, R-Utah, a member of the Finance and Health committees, reported owning between $1,001 and $15,000 worth of stock in drug maker Pfizer Inc. He spoke to two pharmaceutical industry conferences last year. Sponsors of the conferences donated $3,500 to charities instead of speaking fees, as required by Senate rules.
Like millions of Americans, several senators took a financial hit in 2008. A sampling:
_Sen. Dick Durbin, D-Ill., lost some $100,000 in equity in his home in Springfield and $35,000 in his Chicago condominium. Durbin, who released his tax returns, reported losing $32,259 in various investments last year, including more than $10,400 in Berkshire Hathaway and $5,535 in Fidelity stock.
_Kennedy in 2007 had four trusts each valued between $5,000,001-$25 million. In 2008, only one trust was still in that category while the rest had slipped in value to $1,000,001-$5 million.
_Hatch's investments suffered from the banking crisis. In 2007, he reported assets of between $2,002 and $30,000 in Countrywide Credit Industries Inc. stock. His 2008 financial disclosure lists the value at less than $1,000.
One of Dodd's investments showed a vast improvement.
A new appraisal more than doubled the value of his vacation cottage in Ireland, which has been subject of a Senate ethics complaint filed by a conservative group questioning if the undervalued property was really a gift.
The property is valued at 470,000 euros, or about $660,000, on Dodd's disclosure report.
The previous year's report valued the seaside home, located in County Galway, at between $100,001 and $250,000.
DeAngelis, the spokesman, said Dodd and his wife decided to have the property appraised because they felt it was time to update the information.
Subscribe to:
Posts (Atom)